These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9622056)

  • 21. Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules.
    Bubeník J
    Folia Biol (Praha); 1996; 42(6):295-304. PubMed ID: 9158939
    [No Abstract]   [Full Text] [Related]  

  • 22. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens.
    Melero I; Bach N; Chen L
    Life Sci; 1997; 60(23):2035-41. PubMed ID: 9180357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells.
    McKean DJ; Infante AJ; Nilson A; Kimoto M; Fathman CG; Walker E; Warner N
    J Exp Med; 1981 Nov; 154(5):1419-31. PubMed ID: 6170720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
    Chaux P; Moutet M; Faivre J; Martin F; Martin M
    Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunobiology of the normal and tumor astrocyte].
    Pulver M; Zuber P; de Tribolet N
    Rev Neurol (Paris); 1987; 143(11):711-21. PubMed ID: 3324264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
    Mukherji B; Chakraborty NG; Yamasaki S; Okino T; Yamase H; Sporn JR; Kurtzman SK; Ergin MT; Ozols J; Meehan J
    Proc Natl Acad Sci U S A; 1995 Aug; 92(17):8078-82. PubMed ID: 7644541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.
    Tanaka K; Yoshioka T; Bieberich C; Jay G
    Annu Rev Immunol; 1988; 6():359-80. PubMed ID: 3289570
    [No Abstract]   [Full Text] [Related]  

  • 29. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
    Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C
    J Clin Invest; 2007 Oct; 117(10):3087-96. PubMed ID: 17885685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Processing and regulation mechanisms within antigen presenting cells: a possibility for therapeutic modulation.
    Burster T
    Curr Pharm Des; 2013; 19(6):1029-42. PubMed ID: 23016679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular basis for detection of infectious agents].
    Siegrist CA
    Schweiz Med Wochenschr; 1996 Feb; 126(7):246-54. PubMed ID: 8720322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hepatocellular carcinoma with the cellular tumor vaccines generated by in vitro modification of tumor cells with non gene transfer approaches.
    Wu S; Ma J; Che X; Liu Y; Wang H; Zhao J; Shen F; Xie T; Trojan J; Wu M; Guo Y
    Adv Exp Med Biol; 1998; 451():283-93. PubMed ID: 10026886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
    Ostrand-Rosenberg S
    Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Listeria-based vaccines for cancer treatment.
    Paterson Y; Maciag PC
    Curr Opin Mol Ther; 2005 Oct; 7(5):454-60. PubMed ID: 16248280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major histocompatibility complex class II antigen presentation in Hodgkin's disease.
    Bosshart H
    Leuk Lymphoma; 1999 Dec; 36(1-2):9-14. PubMed ID: 10613445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen presenting cells and mechanisms of antigen presentation.
    Chesnut RW; Grey HM
    Crit Rev Immunol; 1985; 5(3):263-316. PubMed ID: 3884274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?
    Thompson CB
    Cell; 1995 Jun; 81(7):979-82. PubMed ID: 7541314
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.
    Höglund P; Ljunggren HG; Kärre K; Jay G
    Immunol Res; 1990; 9(4):298-313. PubMed ID: 2089075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.